Hey readers! This week brought a regulatory nod worth unpacking: a T1D immunotherapy made from, of all things, genetically engineered cattle just picked up an FDA designation meant to speed its path through review. Here is what that actually buys patients, plus a full sweep of trial milestones, a new insulin, and one surprising finding about COVID and T1D risk.
🧬 SAB-142 gets Fast Track
The U.S. FDA granted Fast Track designation to SAB-142, an immunotherapy candidate aimed at adults with new-onset Stage 3 type 1 diabetes. - We are Healthy
Fast Track is a development-and-review lever, not an efficacy verdict. It recognizes an unmet medical need and lets the sponsor communicate more frequently with the FDA, with potential eligibility for priority review down the line. In plain terms: the data still has to show up, but the paperwork path gets smoother.
The U.S. Food and Drug Administration has granted Fast Track designation to the immunotherapy candidate SAB-142 for the treatment of Stage 3 type 1 diabetes.
SAB-142 itself is unusual. It is developed by SAB Biotherapeutics using genetic engineering in transchromosomic cattle to produce human immunoglobulin G. It is being studied in two trials: the Phase 2b SAFEGUARD trial, for patients within 100 days of a Stage 3 diagnosis, and the broader PRISE-hATG trial, for people diagnosed up to two years prior. SAFEGUARD enrollment is expected to complete in Q4 2026, with topline data anticipated in the second half of 2027.
The company's own announcement confirms the designation and frames it as a step toward potentially faster review for SAB-142. - Markets Insider
The why-it-matters here: Stage 3 is the point of clinical diagnosis, when daily insulin becomes the reality. A therapy that targets the immune process this early is aiming to protect whatever beta-cell function a newly diagnosed person has left. That is management-and-preservation territory, and the 2027 readout is the number to watch.
💉 Trial milestones to track
The Fast Track news arrived alongside a cluster of other T1D programs hitting enrollment and presentation milestones.
vTv completed enrollment of 166 patients in its Phase 3 CATT1 trial of cadisegliatin, an adjunctive therapy for type 1 diabetes, with topline results expected in mid-2027. - Embers
The design is clean: randomized, double-blind, placebo-controlled, with participants taking 800 mg once daily, 800 mg twice daily, or placebo on top of their standard insulin. Cadisegliatin previously earned FDA Breakthrough Therapy designation, so it has its own expedited-development tailwind.
"Completing enrollment for the CATT1 study is a significant milestone for vTv, and we're deeply grateful to the study participants whose commitment made this possible," said Paul Sekhri, Chairman, President and CEO of vTv Therapeutics.
vTv also brought data to the big meeting this week.
vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
A vTv-commissioned, dQ&A-conducted analysis of 674 adults with T1D, including 429 using automated insulin delivery (AID), quantified how common hypoglycemia-related burden still is. - BioSpace
The headline figures are a useful reality check for anyone who assumes modern AID systems solve lows: 24% of adult AID users reported frequent Level 2 hypoglycemia, 12% reported a Level 3 event in the past 12 months, and 17% reported impaired awareness. After accounting for overlap, roughly 54% of AID users were estimated to experience at least one dimension of hypoglycemia-related burden.
These findings reinforce that, despite meaningful advances in insulin delivery technology, insulin has its limitations and hypoglycemia continues to shape daily glucose management for many people with type 1 diabetes.
That is the clinical rationale for adjunctive, non-insulin options like cadisegliatin: not to replace the pump, but to work alongside it.
🧪 On preserving beta cells
A clear walkthrough of the BANDIT trial, which tested the oral JAK inhibitor baricitinib in people aged 10 to 30 within 100 days of diagnosis over 48 weeks. - Gerti Tashko, MD
During treatment, the baricitinib group had higher meal-stimulated C-peptide, lower insulin requirements, and less glucose variability, though HbA1c looked similar between groups. The catch came later: after stopping treatment, the C-peptide advantage narrowed, and by week 96 it was no longer statistically significant.
The brake analogy remains useful here. Baricitinib appeared to slow the decline in insulin production, but the protection weakened after researchers removed that brake.
It is a grounded reminder that early signals and durable benefit are two different questions. The piece also notes that on June 12, 2026, the FDA granted accelerated approval to teplizumab to delay declining insulin production in children aged 8 to 17 with recently diagnosed Stage 3 T1D, a different population and pathway.
💊 Approvals, devices, and tools
A Weekly Insulin Is Now FDA-Approved: The FDA approved Eli Lilly's once-weekly basal insulin efsitora alfa-gobe (Onswik) on September 24, 2026, which could cut basal injections from roughly 365 to 52 per year. Note the fine print for this audience: it is approved for type 2 diabetes only and is not recommended for type 1, with T1D safety data still under evaluation due to hypoglycemia risk. - ChemicalsBlog
UpDoc's AI Chatbot Just Became the First FDA-Cleared Tool to Set Patients' Insulin Doses Directly: UpDoc V1.0, cleared June 25, 2026, gives adults with type 2 diabetes insulin-titration guidance without requiring a physician to review each recommendation, provided the doctor sets the rules upstream. The open question is reimbursement, and whether payers will treat a cleared conversational tool differently from an uncleared one. - Ai Data News
Insulet Announces Omnipod Discover Now Available in U.S.: Insulet says Omnipod Discover is now available in the U.S.; the available excerpt did not include details on features or pricing. - BioSpace
Chinese team says its all-in-one mini artificial pancreas offers next-gen diabetes care: A coin-sized prototype combining a glucose sensor and insulin micropump in one smartphone-controlled unit, aiming to replace the usual two-patch setup. It has only been tested in mice so far, so temper expectations. - South China Morning Post
🔬 Worth a read
A Danish nationwide registry study presented at EASD in Milan found that people under age 30 who had COVID-19 had a statistically significant 16% lower risk of later developing T1D. - healthmedicinet
The nuance matters more than the headline. The reduced risk was time-limited (31 to 180 days after infection), confined to unvaccinated people (24% lower), and in the full population reached significance only among females (26% lower). The authors are careful about it.
The study is observational in nature, which means we cannot say for sure that the reduced risk of type 1 diabetes was caused by SARS-CoV-2 infection.
This is a hypothesis-generating signal, not practical advice. No one should read it as a reason to seek out or avoid anything.
Much of this week's news traces back to CRC 2026, held in Philadelphia from October 9 to 11 with more than 80 sessions spanning immunotherapies, AI, and access to care. - Breakthrough T1D
The next congress, CRC 2027, is set for Washington, D.C. from October 15 to 17, 2027. If this week is any guide, it will be where a lot of next year's readouts get their first public airing.
That is the issue. The through-line: early-diagnosis immunotherapy and adjunctive therapies are both moving, but the meaningful proof points land in 2027. Take care of yourselves until then.